期刊文献+

D-聚甘酯抗凝活性与凝血因子Ⅹ/Ⅱ灭活度比值相关性研究 被引量:2

Relationship Between Anticoagulation and Deactivation Ratio on Ⅹ/Ⅱ Factor of D-polymannuronicate
原文传递
导出
摘要 目的通过探索D-聚甘酯抗凝活性与Ⅹ/Ⅱ因子灭活度比值的相关性,推断其可能的抗凝抗栓机制,为临床更加合理应用该药提供参考。方法设4个不同D.聚甘酯剂量组以及空白、肝素钠2个对照组,每组均测定凝血酶原时间(PT),凝血活酶时间(APTT)以及Ⅱ因子、Ⅹ因子的活性,并计算Ⅹ/Ⅱ的灭活度比值。结果在50-150μg·mL-1内,随着D-聚甘酯浓度的增加,其抗凝活性增强,Ⅹ/Ⅱ因子灭活度比值升高。结论D-聚甘酯在发挥抗凝活性时,可能的机制是以灭活凝血酶活性为主,而不是以抑制凝血酶原产生为主。 OBJECTIVE To investigate relationship between anticoagulation and deactivation ratio on Ⅹ/Ⅱ factor of D-polymannuronicate and estimate the anticoagulation mechanism. METHODS Plasma sample was divided into 6 groups: four D-polymannuronicate groups in different doses, one blank group and one heparin sodium group. APTT, PT and the activity of factor Ⅹ/Ⅱ in each group were determined, then the deactivation ratio on Ⅹ/Ⅱ factor was calculated. RESULTS The anticoagulation as well as the deactivation ratio on Ⅹ/Ⅱ factor was enhanced with the increased concentration of D-polymannuronicate of 50-150 μg·mL-1. CONCLUSION The possible anticoagulation mechanism of D-polymannuronicate is deactivating the activity of thrombin rather than inhibiting thrombinogen.
出处 《中国现代应用药学》 CAS CSCD 北大核心 2011年第8期694-696,共3页 Chinese Journal of Modern Applied Pharmacy
基金 中国海洋大学海洋药物教育部重点实验室开放基金资助项目[KLMD(OUC)200808]
关键词 D-聚甘酯 抗凝活性 灭活度比值 相关性 D-polymannuronicate anticoagulation deactivation ratio relationship
  • 相关文献

参考文献7

二级参考文献36

  • 1汤仲明,刘秀文,柴彪新,屠敏.蛋白质多肽类药物药代动力学研究的方法学和实验设计[J].中国药理学与毒理学杂志,1996,10(3):161-168. 被引量:21
  • 2纪明候.海藻化学[M].北京:科学出版社,1997..
  • 3纪明候.海藻化学 第1版[M].北京:科学出版社,1997.103.
  • 4陈正霖 高金成 王学良.褐藻酸 第1版[M].青岛:中国海洋大学出版社,1989.53.
  • 5陈正霖 高金成 王学良.褐藻酸[M].青岛:中国海洋大学出版社,1989.53.
  • 6[1]邓家栋.邓家栋临床血液学[M].上海:上海科技出版社,2003:1488-1489.
  • 7[2]PUSHPINDER S,HUGH OO.Self-managed anticoagulation:Results from a two-year prospective randomized trial with heart valve patients[J].Ann Thorac Surg,2001,72:1523-1527.
  • 8[4]MACLOMHAIR M,LAVELLE SM.The anticoagulant,antithrombotic and haemorrhagic effect of long-term warfarin on expenimental venous and arterial thrombosis in the rat[J].Ir J Med Sei,1996,165:213-218.
  • 9Leizorovicz A, Haugh MC, Chapuis FR, et al. Low molecular weight heparin in prevention of perioperative thrombosis [ J].BMJ ,1992,305(6859) :913 - 920.
  • 10Cohen M, Theroux P, Borzak S, et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin:the ACUTE Ⅱ study. The Antithrombotic Combination Using Tirofiban and Enoxaparin [J ].Am Heart J,2002,144(3) :470 - 477.

共引文献12

同被引文献8

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部